TriOncoFAP-GlyPro-MMAE is a small molecule drug conjugate (SMDC) that targets fibroblast activation protein (FAP), with an IC50 value of 13 pmol/L. It comprises a ligand targeting FAP (TriOnco), a cleavable glycine-proline linker, and a cytotoxic payload (MMAE).
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted